Cardiovascular medications and long-term mortality among stroke survivors in the Brazilian Study of Stroke Mortality and Morbidity (EMMA)

Geriatr Gerontol Int. 2022 Sep;22(9):715-722. doi: 10.1111/ggi.14429. Epub 2022 Aug 3.

Abstract

Aim: To investigate the association between medication use and long-term all-cause mortality in a Brazilian stroke cohort.

Methods: Both ischemic and hemorrhagic stroke were evaluated. Medication use was assessed as: never, only pre-stroke, only post-stroke, and continuous use. We evaluated anti-hypertensives, anti-diabetics, lipid-lowering drugs, anti-platelets, and anti-coagulants. Cox regression models were adjusted for sociodemographic and cardiovascular risk factors.

Results: Among 1173 incident stroke cases (median age: 68; 86.8% were ischemic, 70% first-ever stroke), medication use was low (overall: 17.5% pre-stroke, 26.4% post-stroke, and 40% were under continuous use). Anti-hypertensives and anti-platelets (aspirin) were the continuous cardiovascular medications used most often, at 83.5% and 72%, respectively, while statins (39.7%) and anti-diabetics (31.3%) were the least used. Medication use (pre-stroke, post-stroke and continuous use) was associated with a reduction in all-cause mortality risk, particularly among those under continuous use (multivariable hazard ratio, 0.52; 95% confidence interval (CI), 0.46-0.66) compared with never-users. Among ischemic stroke patients, this effect was similar (multivariable hazard ratio, 0.52; 95% CI, 0.40-0.68). No significant associations were evident among hemorrhagic stroke patients.

Conclusions: The risk of all-cause mortality was reduced by 48% among those with ischemic stroke under continuous use of medications. Secondary prevention should be emphasized more strongly in clinical practice. Geriatr Gerontol Int 2022; 22: 715-722.

Keywords: mortality of stroke; stroke epidemiology; stroke secondary prevention and medication use.

MeSH terms

  • Aged
  • Antihypertensive Agents
  • Brazil / epidemiology
  • Hemorrhagic Stroke*
  • Humans
  • Ischemic Stroke*
  • Morbidity
  • Risk Factors
  • Stroke* / complications
  • Survivors

Substances

  • Antihypertensive Agents